Celltrion (068270)

[Business Overview] Celltrion is Korea's largest biopharmaceutical company, focused on biosimilar development and manufacturing. Its biosimilar portfolio includes Remsima (infliximab — Remicade biosimilar), Truxima (rituximab — Rituxan biosimilar), Herzuma (trastuzumab — Herceptin biosimilar), and Yuflyma (adalimumab — Humira biosimilar), commercialized globally through partnerships and direct sales channels. Celltrion completed the merger with Celltrion Healthcare in late 2023, consolidating manufacturing and commercialization under one entity. [Core Competitiveness] Celltrion's competitive position rests on a deep biosimilar pipeline, regulatory experience across FDA/EMA/MFDS, and growing direct-sales infrastructure in the US and Europe. The Yuflyma adalimumab launch in the US marks Celltrion's transition from licensing-out to direct distribution at scale. [Earnings Analysis] 2024–2025 results reflected the post-merger integration and growing direct-distribution profitability. Operating margin expansion came from US Yuflyma ramp and reduced reliance on third-party distributors. [Financial Health] Net cash position with conservative leverage. Capital allocation is split between novel-biologic R&D, biosimilar pipeline, and shareholder returns. [Outlook] Yuflyma US share gains versus other adalimumab biosimilars, novel pipeline (CT-P42 aflibercept, CT-P53 daratumumab), and ADC platform development are the principal earnings drivers. Risks include US biosimilar pricing pressure and intensifying competition from Sandoz, Boehringer, and Pfizer biosimilars.